Jafron Biomedical, a global leading provider of technology, product and therapy service in hemoadsorption industry, officially launched its new hemoadsorption equipment -- Future F20 on January 29th, 2022.

Prof. Claudio Ronco (Italy), Prof. Romina A. Danguilan (the Philippines) and Prof. Haibo Liu (China) gave scientific lectures online at the launch ceremony demonstrating the development journey of blood purification devices, especially the importance of hemoadsorption machines.

With the slogan of "Adsorption in Your Hands," Future F20, the professional platform supporting an array of adsorption therapies, is equipped with a practical and user-friendly interface as well as a stable monitoring system. Combined with Jafron hemoperfusion cartridges, Future F20 is ideal for conducting adsorption therapies for patients with acute poisoning, hyper inflammation status, autoimmune disorder, liver dysfunction, etc. It provides an innovative method with high flexibility in hemoperfusion and plasma adsorption therapies, including HP, PA, and DPMAS®. Moreover, the USB connection enables Future F20 to facilitate a convenient review, storage, and sharing of treatment data for further diagnosis.  

Jafron released Future F20 in global markets due to its commitment to serving patients worldwide with adsorption technologies and extracorporeal therapies. As Ms. Caroline Jin, Vice President of Jafron Biomedical, stated in her opening at the ceremony, "Jafron has been providing the support of service, product and technology to our customers in more than 80 countries worldwide ." With this step forward, she believes that Jafron wil better serve our patients and contribute to the life-saving campaign.